Implant Location Articles & Analysis
14 news found
In this article we detail everything you need to capture to design and all on x type of restoration so you can quickly print a prosthesis and deliver it to your patient as quickly after surgery as possible. We think it is best to start with the end in mind and work backwards to the models you need to ...
ByCAD-Ray
Steve Herbst of Central Indiana Orthopedics in Muncie, Indiana. “The BioPoly Great Toe implant addresses a large unmet need in the market, and we are thrilled to have it available in the U.S. now. This small implant has a lot of technology packed into it and solves many of the issues that have caused other great toe implants to ...
This team developed a best-in-class product that performs automated segmentation and reconstruction of imaging data, allowing surgeons to have functional visualization of their surgical cases prior to entering the operating room and without needing external data processing. Surgeons can optimize implant size, location and orientation by digitally placing the ...
Food and Drug Administration has granted clearance for its BioPoly® Great Toe Implant. With this FDA clearance, the BioPoly technology is available for the first time in the U.S. BioPoly first received regulatory approval in 2012 for its knee implants in Europe. “Although we have been in patients in Europe with our knee implants for ...
The key feature of the Company’s implants is the BioPoly® material, which is a patented combination of ultra-high molecular weight polyethylene and hyaluronic acid. The material is essentially a “self-lubricated” polymer that is extremely biocompatible with cartilage tissues. After it is implanted, the BioPoly® material attracts joint ...
The Company was granted another international patent for its partial resurfacing implants which protects the innovative implant designs. In addition to patents that cover the design of its implants, several U.S. and international patents have also been granted that address the Company’s unique BioPoly® material. ...
FORT WAYNE, IN – BioPoly LLC has announced that another U.S. patent has been granted for its partial resurfacing implants which protects the innovative implant designs. The Company’s intellectual property portfolio also consists of patents that address its unique BioPoly® material. ...
The overall safety profile of cataract surgery plus implantation of the Hydrus Microstent was similar to cataract surgery alone, including stabilization of endothelial cell density loss (ECL) from 2 to 3 years and from 3 to 4 years. ...
The Company’s partial resurfacing implants feature its unique BioPoly® material, a patented combination of hyaluronic acid (“Bio”) and ultra-high molecular weight polyethylene (“Poly”). The material behaves like a synthetic cartilage, allowing the implants to replace the damaged cartilage of a patient’s joint rather than ...
Where some of the other BioPoly patents address the design of the implants, this patent family focuses on the material itself. This most recent patent, regarding material derivatives, adds to the Company’s intellectual property portfolio to provide the assurance that all aspects of the implants, material, and surgical technique are protected throughout the ...
Conditions such as corneal haze, corneal opacity, or other conditions may inhibit gonioscopic view of the intended implant location. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, peripheral anterior synechiae (PAS), angle closure, rubeosis, and any other angle abnormalities that could lead to improper placement of ...
Neuspera is focused on developing techniques to transfer power to implants from outside the body, using electromagnetic waves—to allow for smaller, sealed implant designs, compared to battery-powered neuromodulation devices. ...
Medical-grade colorized silicone is applied to the implant to match a patient’s natural iris, based on a selected color photograph, producing a nearly exact match to the patient’s other eye. After surgical implantation of the CUSTOMFLEX ® ARTIFICIALIRIS, patients can go home the same day. ...
The software uses cardiac CT patient data sets to determine which heart failure patients may benefit from implantation of a Cardiac Resynchronization Therapy device and can guide the placement of leads to ensure that the device is effective. ...